Back to Journals » Cancer Management and Research » Volume 1

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

Authors Shults K, Flye L, Green L, Daly T, Manro JR, Lahn M

Published 15 May 2009 Volume 2009:1 Pages 49—59

DOI https://doi.org/10.2147/CMAR.S5611

Review by Single-blind

Peer reviewer comments 6


Keith Shults1, Leanne Flye1, Lisa Green2, Thomas Daly2, Jason R Manro2, Michael Lahn2

1Esoterix, Brentwood, TN, USA; 2Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN, USA

Abstract: Multiparametric analyses of phospho-protein activation in patients with acute myeloid leukemia (AML) offers a quantitative measure to monitor the activity of novel intracellular kinase (IK) inhibitors. As recent clinical investigation with FMS-like tyrosine-3 inhibitors demonstrated, targeting IK with selective inhibitors can have a modest clinical benefit. Because multiple IKs are active in patients with AML, multikinase inhibitors may provide the necessary inhibition profile to achieve a more sustained clinical benefit. We here describe a method of assessing the activation of several IKs by flow cytometry. In 40 different samples of patients with AML we observed hyper-activated phospho-proteins at baseline, which is modestly increased by adding stem cell factor to AML cells. Finally, AML cells had a significantly different phospho-protein profile compared with cells of the lymphocyte gate. In conclusion, our method offers a way to determine the activation status of multiple kinases in AML and hence is a reliable assay to evaluate the pharmacodynamic activity of novel multikinase inhibitors.

Keywords: leukemia, AML, bone marrow, flow cytometry

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]